Search hospitals > Illinois > Urbana
Carle Cancer Center
Claim this profileUrbana, Illinois 61801
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
793 reported clinical trials
16 medical researchers
Summary
Carle Cancer Center is a medical facility located in Urbana, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Carle Cancer Center is involved with conducting 793 clinical trials across 599 conditions. There are 16 research doctors associated with this hospital, such as Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, Kendrith Rowland, MD, and Suparna Mantha.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Vamsi K. VasireddyCarle Cancer Center2 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
30 reported clinical trials
55 drugs studied
Maria T. Grosse-PerdekampCarle Cancer Center2 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
29 reported clinical trials
60 drugs studied
Kendrith Rowland, MDCarle Cancer Center1 year of reported clinical research
Expert in Cancer
Studies Breast Cancer
29 reported clinical trials
59 drugs studied
Suparna ManthaCarle Cancer Center4 years of reported clinical research
Studies Cancer
Studies Adenocarcinoma
29 reported clinical trials
64 drugs studied
Clinical Trials running at Carle Cancer Center
Breast Cancer
Lung Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Cancer
Squamous Cell Carcinoma
Gastric Cancer
Tumors
Esophageal Cancer
Multiple Myeloma
Ribociclib vs. Palbociclib
for Breast Cancer
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 sites worldwide. In addition, the HARMONIA trial will include an exploratory cohort of patients with HR+/HER2- and Basal-like disease treated with paclitaxel +/- Tislelizumab. This cohort does not have a predefined sample size and the objective is only exploratory, given the suggested lack of efficacy of the combinations of hormone therapy and CDK4/6 inhibitors in this subgroup of patients. Enrolment into the basal-like cohort will stop once the HER2-E disease cohort is fully enrolled.
Recruiting4 awards Phase 311 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Carle Cancer Center?
Carle Cancer Center is a medical facility located in Urbana, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Carle Cancer Center is involved with conducting 793 clinical trials across 599 conditions. There are 16 research doctors associated with this hospital, such as Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, Kendrith Rowland, MD, and Suparna Mantha.
Where is Carle Cancer Center located?
**Carle Cancer Institute, Urbana, IL**
- **Address:** 509 W. University Ave, Urbana, IL
- **Phone:** (217) 383-3010
- **Facility Type:** Outpatient
- **Additional Information:** For parking and further details, please visit the official Carle website.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Carle Cancer Center, contact Carle Patient Financial Services at (888) 71-CARLE, (888) 712-2753, available Monday through Friday, 8 a.m. to 5 p.m. Translated copies of Carle Financial Assistance Program materials are available in Spanish at Carle.org/FinancialAssistance or by request at FinancialAssistance@Carle.com. To apply for financial assistance, download the application from the Carle Health website or contact them for assistance.
What insurance does Carle Cancer Center accept?
The Carle Cancer Center accepts a range of insurance plans, including Carle Health, Medicare, Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealthcare. Coverage may vary by location and service type. Patients should verify their plan's coverage for in-network or out-of-network benefits.
What awards or recognition has Carle Cancer Center received?
Carle Cancer Center in Urbana, Illinois, is supported by the Cancer Center at Illinois 2022 grants, enhancing cancer research collaborations on the University of Illinois Urbana-Champaign campus. It is also recognized for its research efforts through the Stephens Family Clinical Research Institute, focusing on new discoveries and best practices in healthcare.